Matthew Winton is COO of Inozyme Pharma, Inc.. Currently has a direct ownership of 0 shares of INZY, which is worth approximately $0. The most recent transaction as insider was on Jul 01, 2025, when has been sold 21,743 shares (Common Stock) at a price of $4.0 per share, resulting in proceeds of $86,972. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0
100.0% 3M change
100.0% 12M change
Total Value Held $0

Matthew Winton Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jul 01 2025
SELL
Disposition due to a tender of shares in a change of control transaction
$86,972 $4.0 p/Share
21,743 Reduced 100.0%
0 Common Stock
Jun 25 2025
BUY
Grant, award, or other acquisition
$10,622 $0.74 p/Share
14,355 Added 39.77%
21,743 Common Stock
Mar 31 2025
BUY
Grant, award, or other acquisition
$1,917 $0.77 p/Share
2,490 Added 25.21%
7,388 Common Stock
Sep 30 2024
BUY
Grant, award, or other acquisition
$7,609 $4.45 p/Share
1,710 Added 25.88%
4,898 Common Stock
Mar 28 2024
BUY
Grant, award, or other acquisition
$10,616 $3.33 p/Share
3,188 Added 50.0%
3,188 Common Stock
MW

Matthew Winton

COO
Boston, MA

Track Institutional and Insider Activities on INZY

Follow Inozyme Pharma, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells INZY shares.

Notify only if

Insider Trading

Get notified when an Inozyme Pharma, Inc. insider buys or sells INZY shares.

Notify only if

News

Receive news related to Inozyme Pharma, Inc.

Track Activities on INZY